Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
about
Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapyHIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialEnhancement of protective efficacy through adenoviral vectored vaccine priming and protein boosting strategy encoding triosephosphate isomerase (SjTPI) against Schistosoma japonicum in mice.Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85AOvercoming tumor resistance by heterologous adeno-poxvirus combination therapy.Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.Evaluation of protective efficacy induced by different heterologous prime-boost strategies encoding triosephosphate isomerase against Schistosoma japonicum in mice.The alien replicon: Artificial genetic constructs to direct the synthesis of transmissible self-replicating RNAs: In vivo synthesised heterologous (alien) RNA constructs are capable of initiating self-replication following transmission to the host oCD8 T cells and Mycobacterium tuberculosis infection.Development of replication-deficient adenovirus malaria vaccines.The current status, challenges, and future developments of new tuberculosis vaccines.Recent developments in tuberculosis vaccines
P2860
Q35069876-2228B9E4-0DFD-48B9-BE45-09FA6419C2ABQ35140001-1F548D51-2753-46C5-AEE2-348B8E391DFAQ35202806-2F0A935C-E386-4083-9DBF-419D4D3842D3Q36369598-D0F27CF2-4F71-4929-99B1-DC6CF33ED85EQ36664229-A93A3D93-B048-406D-BE87-8F0385E7A781Q36980878-A3E6B130-64E8-4A8E-8D6A-9673C1FDEB91Q37671401-7594F435-373F-4738-9AC0-6F4096A4616CQ38266429-40DB4C26-FC55-4580-BE36-F55EFE26FBA5Q38445065-E4EB7B3F-E7A4-4264-9E28-E8034DA9C272Q38949194-326CC5AD-8B1C-4473-8BA9-139ADE00F3BEQ52337140-B70497FF-64E9-4D33-A69F-52205839EE52Q58834925-D2BDCDE5-46FE-43DF-B9A1-3EB9E375EB27
P2860
Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Optimising immunogenicity with ...... n Ag85A in a single injection.
@ast
Optimising immunogenicity with ...... n Ag85A in a single injection.
@en
Optimising immunogenicity with ...... n Ag85A in a single injection.
@nl
type
label
Optimising immunogenicity with ...... n Ag85A in a single injection.
@ast
Optimising immunogenicity with ...... n Ag85A in a single injection.
@en
Optimising immunogenicity with ...... n Ag85A in a single injection.
@nl
prefLabel
Optimising immunogenicity with ...... n Ag85A in a single injection.
@ast
Optimising immunogenicity with ...... n Ag85A in a single injection.
@en
Optimising immunogenicity with ...... n Ag85A in a single injection.
@nl
P2093
P2860
P50
P1433
P1476
Optimising immunogenicity with ...... n Ag85A in a single injection.
@en
P2093
Adrian Hill
Elena Stylianou
Gareth Betts
Hazel Poyntz
P2860
P304
P356
10.1371/JOURNAL.PONE.0050447
P407
P577
2012-12-21T00:00:00Z